A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.

@article{Tandon2016ADP,
  title={A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.},
  author={Rajiv Tandon and Josephine B. Cucchiaro and Debra Phillips and David D{\'i}ez Hern{\'a}ndez and Yongcai Mao and Andrei S Pikalov and Antony D. Loebel},
  journal={Journal of psychopharmacology},
  year={2016},
  volume={30 1},
  pages={69-77}
}
OBJECTIVE To evaluate the effectiveness of lurasidone as maintenance treatment for schizophrenia. METHOD Adults experiencing an acute exacerbation of schizophrenia initially received 12-24 weeks of open-label treatment with lurasidone (40-80 mg/d, flexibly dosed). Patients who maintained clinical stability for ⩾12 weeks were randomized in double-blind fashion to placebo or lurasidone (40-80 mg/d, flexibly dosed) for an additional 28-week treatment period. The primary efficacy endpoint was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Effectiveness of lur

  • L Citrome, PJ Weiden, JP McEvoy
  • 2014
2 Excerpts

Similar Papers

Loading similar papers…